Abstract:The rapid development of a stereoselective route for CXCR7 antagonist ACT-1004-1239 was needed, as the large-scale chromatographic separation of enantiomers was not a viable option for a resupply campaign that targeted >30 kg of API. The key to success was the stereoselective reduction of a chiral enamine derived from inexpensive (S)-α-methylbenzylamine. The reduction showed good selectivity for the desired cis-3R,4S-isomer, and the pure diastereomer (d.r. >98:2) was isolated as its TFA salt. After removal of the ethylbenzyl group and amide coupling with 5-(2,4-difluorophenyl)isoxazole-3-carboxylic acid, the enantiopure cis-3R,4S-amide was isolated. The subsequent epimerization of the 3-position adjacent to the methyl ester turned out to be a formidable challenge, as the standard conditions with NaOMe led to the formation of a thermodynamic mixture of the cis and trans isomers (final ratio of ∼1:4). Therefore, a new procedure was developed in which the methyl ester was transesterified in situ to the isopropyl ester with KOiPr in iPrOH, followed by epimerization to the trans-iPr-ester (final cis:trans ratio 5:95). After saponification with aqueous KOH, the desired trans-3S,4S-acid was isolated in overall 76% yield. After amide coupling and Boc deprotection, the final reductive amination with cyclopropanecarboxaldehyde was also vastly improved. A novel NaBH(OAc)3 solution in DMSO was used for the reaction and cleanly provided the API with high purity after simple aqueous quench without the need for any solvent switches or aqueous workups. As a proof of concept, 240 g of API was produced in house with the novel stereoselective route, which was then also used to produce over 30 kg of GMP material at an external manufacturer for Phase 2 clinical studies.

Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 1: Introduction and Process Overview

Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 3─Development of a Scalable Enzymatic Oxidation Process

Development Of A Concise, Scalable Synthesis Of A Ccr1 Antagonist Utilizing A Continuous Flow Curtius Rearrangement

Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 1─Process History and Development Strategy

Manufacturing Process Development for Belzutifan, Part 2: A Continuous Flow Visible-Light-Induced Benzylic Bromination

Single‐ and Multiple‐Dose Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, in Healthy Adults

Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space

Development of a Cost-Efficient Process Toward a Key Synthetic Intermediate of the EZH2 Inhibitor PF-06821497

Design and Optimization of a Greener Sinomenine Hydrochloride Preparation Process Considering Variations among Different Batches of the Medicinal Herb

Toward the Development of a Manufacturing Process for Milvexian: Scale-Up Synthesis of the Side Chain

Early Process Development of CH7057288, a Benzofuran-Containing Selective NTRK Inhibitor

A Simple and Effective Method for the Preparation of High-Purity Shikimic Acid from Chromatography Wash Effluent of Ginkgo Biloba Leaf Extract by Macroporous Resin Considering the Effect of Varying Feed Solution Compositions.

Early Process Development and Scale-Up of a Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor

Manufacturing Process Development for Belzutifan, Part 6: Ensuring Scalability for a Deoxyfluorination Reaction

Green Solvent Mixtures for Solid-Phase Peptide Synthesis: A Dimethylformamide-Free Highly Efficient Synthesis of Pharmaceutical-Grade Peptides

An Optimized Scalable Fully Automated Solid-Phase Microwave-Assisted cGMP-Ready Process for the Preparation of Eptifibatide

Development of a Scalable Synthesis of Mevidalen (LY3154207), an Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor

A Green Approach to Producing Polymer Microparticles for Local Sustained Release of Flavopiridol

Development of a Scalable, Stereoselective Second-Generation Route for CXCR7 Antagonist ACT-1004-1239 via Chiral Enamine Reduction and a Novel Telescoped Sequence of Transesterification, cis -to- trans Epimerization, and Saponification

Scalable Process of Spiro(cyclopropane)oxazepane Pyridine Carboxylic Acid Through Kulinkovich, Mitsunobu, and Pd-Catalyzed Intramolecular C–N Coupling

Process Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849)